Basic Addyi Information

• INN (International Nonproprietary Name): Flibanserin
• Brand Names Available In Canada (English): Addyi (100 mg oral tablets, blister packaging)
• ATC Code: G02CX02
• Forms & Dosages: Tablet, oral — 100 mg — Sprout Pharmaceuticals — Blister packs (usually 30-tablet supply per carton)
• Manufacturers In Canada (English): Sprout Pharmaceuticals, Inc. (marketed product; sole approved supplier as of 2025)
• Registration Status In Canada (English): Approved by Health Canada for the indicated population
• OTC / Rx Classification: Prescription only (Rx)
• Standard Dosages Per Condition: Indication — Acquired, generalized Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women; Recommended Dose — 100 mg orally once daily at bedtime
• Dosage Adjustments: Children — Not approved; Elderly — Not recommended; Liver Impartment — Contraindicated in severe hepatic impairment; Renal Impairment — Insufficient data
• Typical Treatment Duration & Regimen: Once daily at bedtime; assess benefit after 8 weeks and discontinue if no benefit
• Missed Dose / Overdose: Skip missed dose and take next dose at regular time; do not double the dose. Overdose — supportive care; severe hypotension, drowsiness, syncope possible; seek immediate medical attention
• Storage And Transport: Store at 20–25°C (68–77°F). Protect from moisture and excessive heat. Keep in original packaging
• Absolute Contraindications: Severe hepatic impairment; concomitant use with moderate or strong CYP3A4 inhibitors; known hypersensitivity to flibanserin or excipients
• Relative Contraindications / Cautions: Alcohol use (co-use associated with severe hypotension); use with CNS depressants or certain psychotropic drugs; history of hypotension or syncope; mild/moderate hepatic or renal impairment requires clinical judgment
• Common Side Effects: Dizziness; sleepiness (somnolence); nausea; insomnia; dry mouth
• Competitive Landscape: First approved oral pharmacologic treatment for HSDD in women; alternatives include injectable bremelanotide (Vyleesi), off-label testosterone, and compounded options (not Health Canada approved for HSDD)
• Word-Use Cases / Search Terms: “Addyi tablets 100mg”, “flibanserin 100 mg”, “Hypoactive sexual desire treatment for women”
• Additional Notes: Addyi targets sexual desire centrally and is not a treatment for physical arousal disorders; efficacy established only in premenopausal women with acquired, generalized HSDD

Immediate Safety

Do not take Addyi (flibanserin) with alcohol because co-use increases the risk of severe hypotension and syncope.

Do not take Addyi with moderate or strong CYP3A4 inhibitors; this combination is contraindicated due to increased flibanserin levels and hypotension risk.

Do not use Addyi if you have severe liver impairment; this is an absolute contraindication.

If fainting, severe dizziness, or extreme drowsiness occurs after a dose, seek urgent medical care or call emergency services.

Daily-Life Integration

Plan dosing at bedtime using the recommended 100 mg once daily dose to reduce next-day somnolence and dizziness.

Assess treatment benefit after 8 weeks and stop if there is no improvement in symptoms.

If you have night-shift duties or expect to be awake and alert overnight, avoid taking Addyi on those nights and discuss alternatives with your prescriber.

Pharmacy Logistics

Addyi requires a prescription under Health Canada regulation; confirm the prescription at your pharmacy before dispensing.

Check the package for the Health Canada Drug Identification Number (DIN) and the patient leaflet before starting therapy.

Buy only from licensed Canadian pharmacies in person or verified online chains such as Shoppers Drug Mart, Rexall, Jean Coutu, and London Drugs.

Rural Access

In smaller communities, book a telepharmacy or primary-care appointment early to avoid delays in access and to allow time for prior authorization paperwork.

Provincial drug plans (Ontario ODB, BC PharmaCare, RAMQ) may require prior authorization for coverage; verify coverage and paperwork before purchasing.

Practical Checklist

• Confirm prescription, DIN, and English/French leaflet with pharmacist.
• Plan to take Addyi at bedtime on alcohol-free nights.
• Discuss current medications and supplements with the pharmacist for CYP3A4 interactions.
• Arrange telepharmacy or early appointment if living in a rural area.
• Monitor for dizziness, somnolence, or syncope and know when to seek urgent care.

Everyday Use & Best Practices

Morning Vs Evening Dosing In Canadian Routines

Which time of day is best for Addyi matters because drowsiness and dizziness are common side effects.

The recommended routine is to take Addyi 100 mg once daily at bedtime to minimise next-day impairment.

For Canadians with early-morning work schedules, bedtime dosing means taking the tablet right before sleep, not before leaving for work.

Avoid dosing when planning to wake for night-shift responsibilities or early emergency shifts.

If travelling across time zones, continue taking Addyi at local bedtime and consult your prescriber for complex schedule changes.

Taking With Or Without Meals (Canadian Diet Context)

There is no strict requirement to take Addyi with or without food according to product information.

Avoid taking Addyi after heavy alcohol-containing meals or social events that include drinking; alcohol is contraindicated.

A light snack before bedtime is acceptable and can help with tolerability for some patients.

In bilingual households, review English and French labelling and request pharmacist counselling in the preferred official language.

Practical Tip

• Daily bedside routine: take Addyi 100 mg at bedtime on alcohol-free nights.
• Use a medication reminder app or a bedside checklist to improve adherence.
• If no benefit after 8 weeks, stop and discuss alternatives with your prescriber.

Safety Priorities

Who Should Avoid It (Health Canada Advisories)

Do not use Addyi if you have severe hepatic impairment; this is an absolute contraindication in Health Canada labelling.

Do not use Addyi with moderate or strong CYP3A4 inhibitors such as certain azole antifungals, macrolide antibiotics, or some antiretrovirals; concomitant use is contraindicated.

Do not use Addyi if you have a known hypersensitivity to flibanserin or any excipient listed in the leaflet.

Discuss use with your prescriber if you have a history of hypotension, syncopal episodes, or take central nervous system depressants.

Activities To Limit (Driving, Workplace Safety)

Avoid driving or operating heavy machinery when starting Addyi or after dose changes until you know how it affects you.

The risk of dizziness and somnolence can impair reaction time and ability to perform safety-critical tasks.

Shift workers should consider occupational risks and consult occupational health before starting treatment.

Avoid alcohol entirely while on Addyi due to the risk of severe hypotension and syncope; this is a strict product guidance point.

Practical Aids

Request a pharmacist counselling note summarizing restrictions for employers or occupational health when accommodations are required.

Contraindications	Precautions
Severe hepatic impairment	Mild/moderate hepatic impairment — use clinical judgment
Concomitant moderate/strong CYP3A4 inhibitors	Concurrent CNS depressants — increased somnolence
Known hypersensitivity to flibanserin	History of hypotension or syncope — discuss risks

Dosage & Adjustments

General Regimen (DIN References)

The standard regimen for Addyi is 100 mg orally once daily at bedtime for premenopausal women with acquired, generalized HSDD.

Health Canada labelling requires assessment of benefit after 8 weeks and discontinuation if no clinically meaningful improvement is seen.

Confirm the DIN on the dispensed package with your pharmacy and include it in your medication record for future refills and coverage claims.

Special Cases (Elderly, Comorbidities)

Addyi is not approved for children and is targeted at premenopausal women; its use is not recommended in older or postmenopausal patients based on pivotal trial populations.

Severe hepatic impairment is contraindicated; avoid prescribing in that population.

Renal impairment has limited data, so exercise caution and consult a specialist for severe renal disease.

Patients on CYP3A4 inhibitors require pharmacist review; many such combinations are contraindicated or need alternative treatment strategies.

Practical Tools

Item	Action	Timeline
Starting dose	100 mg nightly at bedtime	Daily
Efficacy check	Assess benefit and tolerability	Week 8
Liver safety	Confirm no severe hepatic impairment	Before starting

User Testimonials

Positive Reports From Canadian Patients

<p“After about a month of taking Addyi at bedtime I noticed a modest increase in interest and it helped conversations with my partner,” reports one anonymous patient on a provincial health forum.

Several Canadian users describe modest improvements in desire after several weeks and say bedtime dosing limited daytime sleepiness.

Pharmacy counselling and provincial supports are commonly mentioned as helpful for adherence and navigation of prior authorization.

Common Challenges In Forums (Reddit Canada, Health Boards)

• Cost and provincial coverage hurdles such as prior authorization requirements.
• Side effects — dizziness and sleepiness are frequently cited as the main downsides.
• Access delays for rural patients and confusion about strict alcohol rules.
• Difficulty obtaining refills when prescribers are unfamiliar with HSDD treatments.

Checklist For Discussion With Prescriber

• Describe benefit timeline and what “modest improvement” means to you.
• List current medications and ask about CYP3A4 interactions.
• Discuss costs, prior authorization steps, and pharmacy options for rural delivery.

Buying Guide

Pharmacy Sources (Shoppers, Rexall, Jean Coutu, London Drugs)

Addyi is dispensed by licensed Canadian pharmacies with a valid prescription; national chains such as Shoppers Drug Mart, Rexall, Jean Coutu, and London Drugs can supply it.

Check packaging for Health Canada labelling and the DIN before accepting the product at pickup or delivery.

Avoid unverified international sellers and listings that offer unauthorized generics; fraudulent generics have been reported online.

Price Comparison (In-Store Vs Online, Cross-Border Notes)

Cost varies by pharmacy, dispensing fees, private insurance, and provincial formulary coverage.

Manufacturer patient-support programs may be available; ask your prescriber or pharmacist about legitimate programs.

Cross-border differences exist — Addyi is marketed in the United States and Canada by Sprout Pharmaceuticals — but importing prescription medicines can be legally complex and is not generally recommended.

Note: In our online pharmacy, addyi is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

What To Bring To The Pharmacy

• Valid prescription.
• Health card for provincial coverage checks.
• Any prior-authorization documentation from your prescriber.

What’s Inside & How It Works

Ingredients Overview

The active ingredient in Addyi is flibanserin (INN), supplied as 100 mg oral tablets by Sprout Pharmaceuticals in primary markets.

Excipients vary by manufacturer and are listed in the package leaflet; check the leaflet for allergy information and hypersensitivity warnings.

Mechanism Basics

Flibanserin acts centrally on neurotransmitter systems implicated in sexual desire, particularly serotonin and dopamine pathways.

This mechanism targets desire rather than peripheral arousal physiology and differs from PDE5 inhibitors used for male erectile dysfunction.

It is distinct from injectable bremelanotide (Vyleesi) and from off-label testosterone approaches, both of which have different modes of action and evidence bases.

Item	Details
Active Ingredient	Flibanserin 100 mg
Form	Oral tablet, blister pack
Manufacturer	Sprout Pharmaceuticals

Main Indications

Approved Uses In Canada

Health Canada has approved Addyi (flibanserin) for acquired, generalized Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women.

The on-label dosing is 100 mg once nightly at bedtime and requires a prescription.

Efficacy should be evaluated after 8 weeks and treatment discontinued if there is no benefit.

Off-Label Uses By Canadian Physicians

Some prescribers may consider off-label use for postmenopausal patients or in combination with psychotherapy, but such uses lack Health Canada approval.

Insurers typically require on-label use for reimbursement, and off-label prescribing should include documented informed consent and rationale in the medical record.

Alternatives like bremelanotide (injectable) or hormonal options may be discussed where appropriate.

Use	On-Label Evidence
Premenopausal Acquired, Generalized HSDD	Approved by Health Canada — 100 mg nightly
Postmenopausal HSDD	Off-label — discuss risks/benefits; not approved

Interaction Warnings

Food Interactions (Alcohol, Caffeine)

Alcohol co-use with Addyi is contraindicated due to the risk of severe hypotension and syncope; even small amounts can increase risk.

Plan social drinking away from initiation and continuation of therapy; discuss safety planning with your clinician and pharmacist.

Caffeine is not specifically contraindicated but may interact with sleep patterns; monitor for insomnia if caffeine is consumed late in the day while on Addyi.

Drug Conflicts (Health Canada Database)

Moderate or strong CYP3A4 inhibitors substantially raise flibanserin exposure and are contraindicated.

Examples include certain azole antifungals, macrolide antibiotics, and some protease inhibitors — confirm exact agents with a pharmacist.

CNS depressants can increase drowsiness and somnolence; review all prescription, OTC, and herbal products including St. John’s wort for potential interactions.

Practical Step

Request a pharmacist-led medication review using the Health Canada drug interaction resources at each refill and keep a printed interaction checklist with your medication.

Interacting Agent	Severity
Alcohol	Contraindicated — severe hypotension/syncope
Moderate/Strong CYP3A4 Inhibitors	Contraindicated — increased exposure
CNS Depressants	Precaution — increased somnolence

Latest Evidence & Insights

Highlight Canadian And International Research

Pivotal clinical trials demonstrated modest but measurable increases in validated desire metrics in premenopausal women taking flibanserin compared with placebo.

Health Canada reviewed similar efficacy and safety data when approving Addyi for the indicated population.

Canadian practice literature emphasises careful patient selection and thorough counselling on side effects such as dizziness, somnolence, and nausea.

Trial	Population	Primary Outcome	Adverse Events
Pivotal Trials (pooled)	Premenopausal women with acquired, generalized HSDD	Modest increase in desire scores vs placebo	Dizziness, somnolence, nausea

Real-World Outcomes (Canadian Practice Notes)

Clinicians in Canada report variable response rates and emphasise that benefits must outweigh side effects for continued use.

Comparative data versus other HSDD interventions are limited; bremelanotide offers a different route and safety/tolerability profile.

Use an evidence-based counselling checklist when initiating therapy and reassess at 8 weeks for clinical decision-making.

Alternative Choices

Comparable Medicines With Pros/Cons Checklist

• Bremelanotide (Vyleesi) — Injectable peptide; pros: alternative mechanism and as-needed dosing; cons: injection route and different adverse events.
• Testosterone (off-label) — Pros: hormonal approach for some patients; cons: off-label, safety concerns, limited approval for HSDD.
• Compounded Products — Pros: tailored dosing; cons: not Health Canada approved for HSDD and variable quality.

Non-Pharmacologic Options And Combined Approaches

Sex therapy, couples counselling, cognitive-behavioural therapy, and lifestyle measures such as improved sleep and stress reduction are effective non-drug strategies.

Combined approaches (psychotherapy plus medication) often yield better patient-centred outcomes than medication alone.

Option	Pros	Cons
Sex Therapy	Addresses psychological and relational factors	Requires time and access to trained therapists
Bremelanotide	Different mechanism; as-needed dosing	Injection; different side-effect profile

Regulation Snapshot

Health Canada Approval And DIN Requirements

Addyi (flibanserin) is approved by Health Canada for HSDD in premenopausal women and is prescription-only.

Always confirm the Health Canada labelling and the DIN on the dispensing package with the pharmacist before starting therapy.

No authorized generics are reported as of 2025 and patent protections affect market availability.

Provincial Formulary And Reimbursement Notes

Provincial drug plans such as Ontario Drug Benefit, BC PharmaCare, and RAMQ may require special authorization or exceptional access for coverage; documentation from the prescriber is usually needed.

Private insurers vary; on-label use is generally preferred for reimbursement claims.

Dispensing Check	Action
DIN Present	Confirm and record for coverage claims
Expiry Date	Verify before accepting medication
Leaflet	Read for contraindications and ingredients

FAQ Section

Can I Drink Wine While Taking Addyi?

No — alcohol with Addyi is contraindicated due to the risk of severe hypotension and syncope; plan treatment on alcohol-free nights and discuss safety with your clinician.

How Long Before I Know It’s Working?

Evaluate efficacy after 8 weeks at the recommended 100 mg nightly dose; discontinue if no benefit is observed.

Will My Pharmacist Need Anything Special To Dispense?

The pharmacist requires a valid prescription and will check your medication profile for contraindications, confirm DIN and coverage options, and provide counselling.

Is There A Canadian Patient Support Program?

Manufacturer patient-support programs may exist; ask your prescriber or pharmacist and confirm program legitimacy before enrolling.

Printable Safety Actions

• Do not drink alcohol while on Addyi.
• Take at bedtime and avoid driving until you know how you react.
• Stop if severe dizziness, fainting, or extreme drowsiness occurs and seek urgent care.

Guidelines For Proper Use

Canadian Pharmacist And Provincial Health Authority Recommendations

Pharmacists should verify prescriptions, screen for contraindicated medicines including moderate/strong CYP3A4 inhibitors, and counsel patients about strict alcohol avoidance.

Provincial health authorities recommend documented informed consent for on-label HSDD treatment and clear monitoring plans for adverse events.

Confirm DIN and labelling language (English/French) at dispensing and provide patient education materials in the requested official language.

Monitoring Checklist (Side Effects, Efficacy)

• Baseline medication reconciliation and review for CYP3A4 inhibitors.
• Confirm no severe hepatic impairment before starting.
• Monitor for hypotension signs, syncope, dizziness, somnolence, nausea, insomnia, and dry mouth.
• Reassess clinical benefit and tolerability at 8 weeks; document and report adverse events.
• Provide a wallet card with emergency instructions for syncope or severe hypotension.

Delivery Across Canada (English)

City	Region	Delivery Time
Toronto	Ontario	5-7 days
Vancouver	British Columbia	5-7 days
Montréal	Quebec	5-7 days
Calgary	Alberta	5-7 days
Ottawa	Ontario	5-7 days
Edmonton	Alberta	5-7 days
Winnipeg	Manitoba	5-7 days
Halifax	Nova Scotia	5-9 days
Saskatoon	Saskatchewan	5-9 days
St. John’s	Newfoundland and Labrador	5-9 days
Victoria	British Columbia	5-9 days
Charlottetown	Prince Edward Island	5-9 days